MSCI Inc.

**Signal Note: MSCI Position Initiation by Eventide** This represents a notable allocation to a financial infrastructure provider rather than a biotech asset—Eventide's entry into MSCI suggests conviction in ESG/values-aligned indexing demand, which has driven MSCI's recurring revenue. The $20.9M position is material for a values-focused manager but signals indirect biotech exposure through MSCI's methodology and index construction rather than direct pipeline risk.